{
  "drug_name": "Mycophenolate_mofetil",
  "url": "https://wikem.org/wiki/Mycophenolate_mofetil",
  "scraped_at": "2026-01-10T07:57:45.207925",
  "sections": {
    "Administration": {
      "text": "Type: Immunosuppressant\nDosage Forms: 250,500; 200mg/mL; IV\nRoutes of Administration: PO, IV\nCommon Trade Names: CellCept",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Adult_Dosing": {
      "text": "",
      "subsections": {
        "Kidney_transplant_rejection_prophylaxis": {
          "text": "1 g PO/IV bid\nStart: IV with in 24h post transplant, continue up to 14 days, switch to PO ASAP; Info: give on empty stomach; stable patients may take with food",
          "tables": []
        },
        "Heart_transplant_rejection_prophylaxis": {
          "text": "1.5 g PO/IV bid\nStart: IV with in 24h post transplant, continue up to 14 days, switch to PO ASAP; Info: give on empty stomach",
          "tables": []
        },
        "Liver_transplant_rejection_prophylaxis": {
          "text": "1.5 g PO BID or 1 g IV bid\nInfo: start IV with in 24h post transplant, continue up to 14 days, switch to PO ASAP; Info: give on empty stomach",
          "tables": []
        },
        "Lupus_nephritis": {
          "text": "1 g PO bid\nInfo: use with\nprednisone\n, consider decease dose 50% after 6mo treatment",
          "tables": []
        }
      },
      "tables": [],
      "links": [
        {
          "text": "prednisone",
          "url": "https://wikem.org/wiki/Prednisone"
        }
      ]
    },
    "Kidney_transplant_rejection_prophylaxis": {
      "text": "1 g PO/IV bid\nStart: IV with in 24h post transplant, continue up to 14 days, switch to PO ASAP; Info: give on empty stomach; stable patients may take with food",
      "subsections": {
        "Heart_transplant_rejection_prophylaxis": {
          "text": "1.5 g PO/IV bid\nStart: IV with in 24h post transplant, continue up to 14 days, switch to PO ASAP; Info: give on empty stomach",
          "tables": []
        },
        "Liver_transplant_rejection_prophylaxis": {
          "text": "1.5 g PO BID or 1 g IV bid\nInfo: start IV with in 24h post transplant, continue up to 14 days, switch to PO ASAP; Info: give on empty stomach",
          "tables": []
        },
        "Lupus_nephritis": {
          "text": "1 g PO bid\nInfo: use with\nprednisone\n, consider decease dose 50% after 6mo treatment",
          "tables": []
        }
      },
      "tables": [],
      "links": [
        {
          "text": "prednisone",
          "url": "https://wikem.org/wiki/Prednisone"
        }
      ]
    },
    "Heart_transplant_rejection_prophylaxis": {
      "text": "1.5 g PO/IV bid\nStart: IV with in 24h post transplant, continue up to 14 days, switch to PO ASAP; Info: give on empty stomach",
      "subsections": {
        "Liver_transplant_rejection_prophylaxis": {
          "text": "1.5 g PO BID or 1 g IV bid\nInfo: start IV with in 24h post transplant, continue up to 14 days, switch to PO ASAP; Info: give on empty stomach",
          "tables": []
        },
        "Lupus_nephritis": {
          "text": "1 g PO bid\nInfo: use with\nprednisone\n, consider decease dose 50% after 6mo treatment",
          "tables": []
        }
      },
      "tables": [],
      "links": [
        {
          "text": "prednisone",
          "url": "https://wikem.org/wiki/Prednisone"
        }
      ]
    },
    "Liver_transplant_rejection_prophylaxis": {
      "text": "1.5 g PO BID or 1 g IV bid\nInfo: start IV with in 24h post transplant, continue up to 14 days, switch to PO ASAP; Info: give on empty stomach",
      "subsections": {
        "Lupus_nephritis": {
          "text": "1 g PO bid\nInfo: use with\nprednisone\n, consider decease dose 50% after 6mo treatment",
          "tables": []
        }
      },
      "tables": [],
      "links": [
        {
          "text": "prednisone",
          "url": "https://wikem.org/wiki/Prednisone"
        }
      ]
    },
    "Lupus_nephritis": {
      "text": "1 g PO bid\nInfo: use with\nprednisone\n, consider decease dose 50% after 6mo treatment",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "prednisone",
          "url": "https://wikem.org/wiki/Prednisone"
        }
      ]
    },
    "Pediatric_Dosing": {
      "text": "",
      "subsections": {
        "Kidney_transplant_rejection_prophylaxis_2": {
          "text": "3 mo-18 yo: Dose: 600mg/m^2 PO bid; Alt: 750mg PO BID for body surf. area = 1.25-1.5 m^2; 1 g PO BID for body surf. area >1.5 m^2; Max: 1 g/dose",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Kidney_transplant_rejection_prophylaxis_2": {
      "text": "3 mo-18 yo: Dose: 600mg/m^2 PO bid; Alt: 750mg PO BID for body surf. area = 1.25-1.5 m^2; 1 g PO BID for body surf. area >1.5 m^2; Max: 1 g/dose",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Special_Populations": {
      "text": "Pregnancy Rating\n: D\nLactation risk\n: possibly unsafe",
      "subsections": {
        "Renal_Dosing": {
          "text": "Adult:\nkidney transplant patients, delayed graft function immediate postop: no adjustment\nkidney transplant patients, outside immediate post-transplant period:CrCl <25: max 1 g bid; HD/PD: no supplement\nheart or liver transplant patients: CrCl <25: weigh risk/benefit; HD/PD: not defined\nPediatric:\nkidney transplant patients, delayed graft function immediate postop: no adjustment\nkidney transplant patients, outside immediate post-transplant period: CrCl <30: max 600mg/m^2/day; HD/PD: no supplement",
          "tables": []
        },
        "Hepatic_Dosing": {
          "text": "Adult: renal transplant with severe hepatic parenchymal disease: no adjustment; other hepatic impairment: not defined\nPediatric: renal transplant with severe hepatic parenchymal disease: no adjustment; other hepatic impairment: not defined",
          "tables": []
        }
      },
      "tables": [],
      "links": [
        {
          "text": "Pregnancy Rating",
          "url": "https://wikem.org/wiki/Drug_Ratings_in_Pregnancy"
        },
        {
          "text": "Lactation risk",
          "url": "https://wikem.org/wiki/Lactation_risk_categories"
        }
      ]
    },
    "Renal_Dosing": {
      "text": "Adult:\nkidney transplant patients, delayed graft function immediate postop: no adjustment\nkidney transplant patients, outside immediate post-transplant period:CrCl <25: max 1 g bid; HD/PD: no supplement\nheart or liver transplant patients: CrCl <25: weigh risk/benefit; HD/PD: not defined\nPediatric:\nkidney transplant patients, delayed graft function immediate postop: no adjustment\nkidney transplant patients, outside immediate post-transplant period: CrCl <30: max 600mg/m^2/day; HD/PD: no supplement",
      "subsections": {
        "Hepatic_Dosing": {
          "text": "Adult: renal transplant with severe hepatic parenchymal disease: no adjustment; other hepatic impairment: not defined\nPediatric: renal transplant with severe hepatic parenchymal disease: no adjustment; other hepatic impairment: not defined",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Hepatic_Dosing": {
      "text": "Adult: renal transplant with severe hepatic parenchymal disease: no adjustment; other hepatic impairment: not defined\nPediatric: renal transplant with severe hepatic parenchymal disease: no adjustment; other hepatic impairment: not defined",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Contraindications": {
      "text": "Allergy to class/drug\nhypersens. to polysorbate 80 (IV form)\nLesch-Nyhan syndrome\nKelly-Seegmiller syndrome\ncaution in elderly patients\ncaution if GI disorder\ncaution if renal disease, severe\ncaution if bone marrow depression\ncaution if PKU (phenylalanine-containing forms)",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Adverse_Reactions": {
      "text": "",
      "subsections": {
        "Serious": {
          "text": "thrombocytopenia\nleukopenia\nneutropenia\nimmunosuppression\ninfection, severe\nopportunistic infection\nviral reactivation\npolyomavirus-assoc. nephropathy\nPML\npure red cell aplasia\nlymphoma\nlymphoproliferative disorders\nmalignancy\nGI bleeding\nGI perforation/ulcer\ncolitis\nacute renal failure\ninterstitial lung disease\npregnancy loss, 1st trimester\ncongenital malformations",
          "tables": []
        },
        "Common": {
          "text": "hypertension\ninfection\ndiarrhea\nperipheral edema\nanemia\nabdominal pain\nconstipation\nleukopenia\nfever\nheadache\nnausea/vomiting\ndyspepsia\nhypotension (rapid IV use)\ndyspnea\ncough\nhypercholesterolemia\nhypokalemia\ntremor\nacne\ninsomnia",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Serious": {
      "text": "thrombocytopenia\nleukopenia\nneutropenia\nimmunosuppression\ninfection, severe\nopportunistic infection\nviral reactivation\npolyomavirus-assoc. nephropathy\nPML\npure red cell aplasia\nlymphoma\nlymphoproliferative disorders\nmalignancy\nGI bleeding\nGI perforation/ulcer\ncolitis\nacute renal failure\ninterstitial lung disease\npregnancy loss, 1st trimester\ncongenital malformations",
      "subsections": {
        "Common": {
          "text": "hypertension\ninfection\ndiarrhea\nperipheral edema\nanemia\nabdominal pain\nconstipation\nleukopenia\nfever\nheadache\nnausea/vomiting\ndyspepsia\nhypotension (rapid IV use)\ndyspnea\ncough\nhypercholesterolemia\nhypokalemia\ntremor\nacne\ninsomnia",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Common": {
      "text": "hypertension\ninfection\ndiarrhea\nperipheral edema\nanemia\nabdominal pain\nconstipation\nleukopenia\nfever\nheadache\nnausea/vomiting\ndyspepsia\nhypotension (rapid IV use)\ndyspnea\ncough\nhypercholesterolemia\nhypokalemia\ntremor\nacne\ninsomnia",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Pharmacology": {
      "text": "Half-life: 17.9h (PO route), 16.6h (IV route)\nMetabolism: liver; CYP450: Info: prodrug converted to mycophenolic acid (MPA)\nExcretion: urine 93% (<1% unchanged), feces 6%",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Mechanism_of_Action": {
      "text": "inhibits B- and T-lymphocyte proliferation",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "References": {
      "text": "epocrates",
      "subsections": {},
      "tables": [],
      "links": []
    }
  }
}